Table 1 Association of missing detrusor muscle with clinicopathological parameters. TUR-BT – Transurethral resection of the bladder tumor, BMI – Body Mass Index, ASA—American Society for Anesthesiologists
From: Absence of detrusor muscle in TUR-BT specimen – can we predict who is at highest risk?
Total | No detrusor muscle in specimen | Detrusor muscle in specimen | p-value | |
|---|---|---|---|---|
No. of TUR-BTs | 2058 (100.0) | 667 (32.4) | 1391 (67.6) | |
Age [yrs; median (IQR)] | 72 (63 – 79) | 71 (61—71) | 72 (64 – 79) | 0.011 |
Sex [n (%)] | ||||
Male | 1619 (78.7) | 518 (32.0) | 1101 (68.0) | 0.440 |
Female | 439 (21.3) | 149 (33.9) | 290 (66.1) | |
BMI [median (IQR)] | 26 (23.3 – 29.0) | 26 (23.0 – 28.7) | 26 (23.6 – 29.0) | 0.651 |
Smoking history [n (%)] | 829 (54.9) | 271 (32.8) | 558 (67.2) | 0.897 |
Oral anticoagulation [n (%)] | 745 (43.5) | 223 (29.9) | 522 (70.1) | 0.183 |
Anesthesia [n (%)] | ||||
General | 1463 (94.6) | 449 (30.7) | 1014 (69.3) | 0.987 |
Regional/Spinal | 80 (5.2) | 23 (30.0) | 56 (70.0) | |
Other | 3 (0.2) | 1 (33.3) | 2 (66.7) | |
ASA score [n (%)] | ||||
≤ ASA 2 | 684 (38.4) | 235 (34.4) | 449 (65.6) | 0.045 |
≥ ASA 3 | 1097 (61.6) | 327 (29.8) | 770 (70.2) | |
Relaxation [n (%)] | ||||
No | 598 (38.8) | 223 (37.3) | 375 (62.7) | < 0.001 |
Yes | 945 (61.2) | 251 (26.6) | 694 (73.4) | |
Photodynamic diagnostic [n (%)] | 1508 (73.3) | 491 (32.6) | 1017 (67.4) | 0.882 |
Duration of surgery [min; median (IQR)] | 41 (28 – 59) | 36 (25 – 54) | 44 (30 – 60) | < 0.001 |
Timing of surgery [n (%)] | ||||
Morning (08–12) | 1122 (60.3) | 345 (30.7) | 777 (69.3) | 0.266 |
Afternoon (12–16) | 739 (39.7) | 246 (33.2) | 495 (66.8) | |
Tumor size [n (%)] | ||||
< 1 cm | 493 (33.2) | 201 (40.8) | 292 (59.3) | < 0.001 |
1 to 3 cm | 363 (24.4) | 111 (30.6) | 252 (69.4) | |
> 3 cm | 630 (42.4) | 153 (24.3) | 477 (75.7) | |
< 3 cm | 856 (57.6) | 312 (36.4) | 544 (63.6) | < 0.001 |
≥ 3 cm | 630 (42.4) | 153 (24.3) | 477 (75.7) | |
Tumor multiplicity [n (%)] | ||||
Single | 1133 (55.1) | 396 (35.0) | 737 (65.0) | 0.006 |
Multiple | 925 (44.9) | 271 (29.3) | 654 (70.7) | |
Tumor stage [n (%)] | ||||
pT0 | 63 (4.2) | 23 (36.5) | 40 (63.5) | < 0.001 |
pTa | 781 (51.9) | 258 (60.4) | 523 (48.5) | |
pT1 | 400 (26.6) | 133 (33.3) | 267 (66.8) | |
pT2 | 241 (16.0) | 2 (0.8) | 239 (99.2) | |
pT3 | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
pT4 | 21 (1.4) | 11 (52.4) | 10 (47.6) | |
Grading [n (%)] | ||||
Low-grade | 621 (41.1) | 212 (34.1) | 409 (65.9) | < 0.001 |
High-grade | 891 (59.9) | 221 (24.8) | 670 (75.2) | |
Histology [n (%)] | ||||
Urothelial | 1473 (71.6) | 423 (28.7) | 1050 (71.3) | < 0.001 |
Squamous cell | 26 (1.3) | 10 (38.5) | 16 (61.5) | |
Adeno-Ca | 6 (1.3) | 1 (16.7) | 5 (83.3) | |
Other | 11 (0.5) | 2 (18.2) | 9 (81.8) | |
No malignancy | 542 (26.3) | 231 (42.6) | 311 (57.4) | |
Concomitant Carcinoma in situ [n (%)] | 281 (18.6) | 73 (26.0) | 208 (74.0) | 0.441 |
Surgeon category | ||||
Senior | 1380 (67.5) | 725 (52.5) | 655 (47.5) | 0.258 |
Junior | 663 (32.5) | 366 (55.2) | 297 (44.8) | |